Clinical characteristics and prognostic factors of patients with solitary plasmacytoma: a multicenter retrospective study [0.03%]
中国多中心单克隆免疫球蛋白病患者临床特征及预后因素的回顾性研究——浆细胞瘤篇
Xuxing Shen,Wenmin Han,Lina Zhang et al.
Xuxing Shen et al.
Background: Solitary plasmacytoma (SP) is a rare plasmacytoma. Research on clinical characteristics and prognostic factors for SP is very limited. Objecti...
Comparative analysis of once-weekly versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma: a meta-analysis [0.03%]
卡非佐米治疗复发和难治性多发性骨髓瘤一周一次与两周一次疗效的比较：一项meta分析研究
Wenhao Yang,Xiangtu Kong,Hui Yu et al.
Wenhao Yang et al.
Background: While carfilzomib has shown effectiveness in treating relapsed or refractory multiple myeloma (RRMM), the best frequency of dosing is still debated. This meta-analysis aims to investigate the differences in sa...
Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain [0.03%]
伊布替尼治疗西班牙真实世界环境下瓦尔登斯特伦巨球蛋白血症患者的回顾性研究
Carlos Fernández de Larrea,Javier Loscertales,Valentín Cabañas et al.
Carlos Fernández de Larrea et al.
Background: Waldenström's macroglobulinemia (WM) is a B-cell neoplasia characterized by the infiltration of lymphoplasmacytic lymphoma cells in the bone marrow and abnormal secretion of IgM paraprotein. Ibrutinib, a Brut...
Prognostic impacts of marital status and other socioeconomic factors in patients with chronic lymphocytic leukemia: an analysis of SEER database [0.03%]
婚姻状况和其他社会经济因素对慢性淋巴细胞白血病患者预后的影响：基于SEER数据库的分析研究
Jing Zhang,Ping Liu,Yilian Yang et al.
Jing Zhang et al.
Background: Marital status has been demonstrated to impact the outcomes of several malignancies. The prognostic role of marital status in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has not been dete...
Managing transient immune complex reactions in patients with paroxysmal nocturnal hemoglobinuria: clinical observations from the COMMODORE 1 and 2 studies [0.03%]
互补3德龙测定管理突发免疫复合物反应在阵发性夜间血红蛋白尿患者中的临床观察：来自COMMODORE 1和2研究的发现
Austin G Kulasekararaj,Jun-Ichi Nishimura,Alexander Röth et al.
Austin G Kulasekararaj et al.
Background: Crovalimab is a novel C5 inhibitor that enables rapid and sustained C5 inhibition with every 4-week subcutaneous maintenance dosing, with the possibility for self-administration. When switching from another C5...
ROCK 2 inhibition with belumosudil for the treatment of chronic graft-versus-host disease: a narrative review [0.03%]
贝卢莫司杜利通过ROCK2抑制治疗慢性移植物抗宿主病：综述
Xiaoqi Wang,Yuqing Liu,Ting Chen et al.
Xiaoqi Wang et al.
Chronic graft-versus-host disease (cGVHD) is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT). The global incidence of cGVHD remains high, despite prophylactic regimens for patients undergoing HS...
Real-world outcomes of azacitidine plus venetoclax in acute myeloid leukemia: a multicenter retrospective cohort study from Thailand [0.03%]
阿扎胞苷联合维奈克拉治疗急性髓系白血病的现实世界预后：来自泰国多中心回顾性队列研究
Thanawat Rattanathammethee,Chantiya Chanswangphuwana,Panachai Silpsamrit et al.
Thanawat Rattanathammethee et al.
Background: Azacitidine (AZA) plus venetoclax (VEN) has emerged as a widely accepted treatment option for acute myeloid leukemia (AML), particularly in older patients or those unfit for intensive chemotherapy. However, re...
Frontline treatment of IDH1-mutated myelodysplastic syndrome with ivosidenib: clinical cases and therapeutic insights [0.03%]
伊伏西汀治疗IDH1突变骨髓增生异常综合征的临床案例及治疗见解
Bana Antonios,Nina Dutton,Salman Fazal
Bana Antonios
Novel small-molecule therapies for myelodysplastic syndromes with IPSS-R ⩾3.5 in patients aged 60 or older: current landscape and challenges [0.03%]
新型小分子疗法治疗≥60岁且IPSS-R评分⩾3.5的骨髓增生异常综合征患者：现状与挑战
Kehao Hou,Xue Dong,Wenyan Niu
Kehao Hou
Myelodysplastic syndromes (MDS), particularly in older adults aged 60 years and above, present significant therapeutic challenges due to poor prognosis and limited treatment options. Higher-risk MDS (HR-MDS), defined by the Revised Internat...
Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 years [0.03%]
抗肿瘤药维奈克拉的现实世界安全性：法国药品警戒系统中5年来的血液系统恶性肿瘤患者用药数据
Alexis Talbot,Pierre-Edouard Debureaux,Agnès Lillo-Le Louet et al.
Alexis Talbot et al.
Background: Venetoclax is the first representative of a new class of targeted therapy, that inhibits selectively B-cell lymphoma-2 (BCL-2), an anti-apoptotic protein, frequently overexpressed in hematological malignancies...